Lakshmi P. Rao Venkata
YOU?
Author Swipe
View article: Supplementary Figure S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Figure S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Immunohistologic images
View article: Supplementary Table S4 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S4 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Peptide sequences included in each subject's personalized NeoVax peptide vaccine
View article: Supplementary Table S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
RNA-sequencing pseudo counts generated via Salmon algorithm
View article: Supplementary Figure S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Figure S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Bar graph displaying number of validated variants for each subject
View article: Supplementary Figure S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Figure S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
CDR3beta sequences ranked by ratio
View article: Supplementary Table S10 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S10 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Differential expression analysis of nCounter CAR-T characterization panel gene expression analyzed via ROSALIND software
View article: Supplementary Figure S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Figure S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
CDR3beta sequences ranked by abundance
View article: Supplementary Table S5 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S5 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
immunoSEQ resolved TCR sequences for each subject PBMCs pre- and post-NeoVax
View article: Supplementary Table S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
CIBERSORTx relative percents of deconvoluted immunocytes
View article: Supplementary Table S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Immunohistochemistry (IHC) quantification of CD3+ and CD8+ T cells from tumor blocks
View article: Supplementary Table S2 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S2 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Mutect2 called and validated variants for each subject and each tumor region from whole exome sequencing data
View article: Supplementary Table S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
TCR clonal analysis via immunoSEQ ANALYZER software and The Immune Epitope Database (IEDB) TCRMatch results
View article: Supplementary Table S1 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S1 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Representativeness of study participants
View article: Supplementary Table S3 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S3 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
pVAC-Seq predicted neoantigens for each subject and each tumor region from whole exome sequencing data
View article: Supplementary Table S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
CIBERSORTx relative percents of deconvoluted immunocytes
View article: Supplementary Table S2 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S2 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Mutect2 called and validated variants for each subject and each tumor region from whole exome sequencing data
View article: Supplementary Table S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
TCR clonal analysis via immunoSEQ ANALYZER software and The Immune Epitope Database (IEDB) TCRMatch results
View article: Supplementary Table S4 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S4 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Peptide sequences included in each subject's personalized NeoVax peptide vaccine
View article: Supplementary Table S3 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S3 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
pVAC-Seq predicted neoantigens for each subject and each tumor region from whole exome sequencing data
View article: Supplementary Table S1 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S1 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Representativeness of study participants
View article: Supplementary Figure S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Figure S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
CDR3beta sequences ranked by abundance
View article: Supplementary Table S10 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S10 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Differential expression analysis of nCounter CAR-T characterization panel gene expression analyzed via ROSALIND software
View article: Supplementary Figure S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Figure S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
CDR3beta sequences ranked by ratio
View article: Supplementary Figure S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Figure S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Immunohistologic images
View article: Supplementary Table S5 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S5 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
immunoSEQ resolved TCR sequences for each subject PBMCs pre- and post-NeoVax
View article: Supplementary Table S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
RNA-sequencing pseudo counts generated via Salmon algorithm
View article: Supplementary Table S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Immunohistochemistry (IHC) quantification of CD3+ and CD8+ T cells from tumor blocks
View article: Supplementary Figure S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Figure S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
Bar graph displaying number of validated variants for each subject
View article: Supplementary Table S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
CIBERSORTx relative percents of deconvoluted immunocytes
View article: Supplementary Table S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Supplementary Table S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma Open
TCR clonal analysis via immunoSEQ ANALYZER software and The Immune Epitope Database (IEDB) TCRMatch results